4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Premature Ejaculation by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 19 ongoing clinical trials involving Premature Ejaculation
Of the 19 trials,8 trials are in Phase II
Furthermore, 4 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Premature Ejaculation by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Premature Ejaculation, a male health condition. The largest number of ongoing clinical trials for Premature Ejaculation is conducted in the Asia-Pacific region. Middle East and Africa and Europe are among some of the other prominent regions engaged in Premature Ejaculation-related drug trials.

Premature Ejaculation related clinical trial sponsor

Sami Labs Ltd, Cairo University, Cosar Pharmaceutical Co, Isfahan University of Medical Sciences, and Christian Medical College Vellore are among other notable clinical trial sponsors involved in Premature Ejaculation. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Premature Ejaculation

Lidocaine and Prilocaine (Fortacin), Dapoxetine and Sildenafil (For Men), and Dapoxetine hydrochloride and Sildenafil citrate (Powerforce) are among the key marketed drugs involving Premature Ejaculation.

Lidocaine and Prilocaine (Fortacin) is a fixed dose combination. It functions via Voltage Gated Sodium Channel (SCN) Blocker mechanism of action. It is formulated as a spray for cutaneous route of administration. Fortacin is indicated for the treatment of primary premature ejaculation in adult men. It is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during penetration). Fortacin was first approved in 2013 and is marketed globally including the UK, France, and Germany by several pharma giants including Plethora Solutions Ltd, and Recordati Pharmaceuticals Ltd.

Dapoxetine and Sildenafil (For Men) is fixed dose combination acts as urological agent. It functions via Phosphodiesterase 5 (PDE5 or EC 3.1.4.) Inhibitor; Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Inhibitor mechanism of action. For Men is formulated as tablets for oral route of administration. For Men is indicated for pre-mature ejaculation. For Men is sold in India by Globela Pharma Pvt Ltd.